MedPath

Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer

Completed
Conditions
Lung Cancer
Registration Number
NCT00213733
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

This is a prospective study of surgically resected samples and lymph nodes of lung cancer patients. For histopathologically positive lymph nodes from a complete resection, the investigators would like to analyse tumor tissue by allelotyping and comparing these results with those observed in the primary lung tumor to establish a cartography of molecular alteration in resected lung cancer. For non histopathologically positive lymph nodes, the investigators would like to research the presence (or not) of micrometastasis by allele-specific PCR (polymerase chain reaction).

Detailed Description

Genetic: It is a prospective study during two years with three years for follow-up. No control group is recruited.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Patients with resectable non-small cell lung cancer (stage I to IIIA), with a complete resection of the tumor and paired lymph nodes.
  • Informed consent is required.
Exclusion Criteria
  • Another cancer
  • Chemotherapy before surgical treatment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (5)

Service de Chirurgie Thoracique, Hôpital Civil

🇫🇷

Strasbourg, France

Service de Pneumologie, Hôpital Lyautey

🇫🇷

Strasbourg, France

Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre

🇫🇷

Strasbourg, France

Service d'Anatomie Pathologique, Hôpital de Hautepierre

🇫🇷

Strasbourg, France

Service de Pneumologie, Hôpital de Hautepierre

🇫🇷

Strasbourg, France

Service de Chirurgie Thoracique, Hôpital Civil
🇫🇷Strasbourg, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.